---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-056966"
form_type: "8-K"
ticker: "SKYE"
cik: "0001516551"
company_name: "Skye Bioscience, Inc."
filed_at: "2026-08-14T13:36:58+00:00"
generated_at: "2026-08-14T13:38:08.120189+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 1.0
calibrated_materiality_score: 1.0
confidence: "high"
source: SEC EDGAR
---

# Skye Bioscience to acquire Redx Pharma; Redx holders to own ~46% of combined company

## Summary
- Skye to acquire Redx Pharma via UK scheme of arrangement; Redx valued at $125M, Skye at $14.5M.
- Post-close ownership: Redx shareholders ~46.17%, Skye ~5.38%, new investors ~48.45% (assuming $67.9M concurrent financing).
- Concurrent financing of $67.9M (up to $72.9M) plus $5M side letter and $22M equity line; warrant valued at $5M.
- Redx management to lead combined company: Lisa Anson CEO, Peter Collum CFO; current Skye executives and board to resign.
- Shareholders to receive CVRs: Skye legacy CVR (90% of net proceeds from certain assets) and Redx CVR (100% of Redx asset proceeds).

## SEC filing metadata
- accession: 0001628280-26-056966
- form_type: 8-K
- ticker: SKYE
- cik: 0001516551
- company_name: Skye Bioscience, Inc.
- filed_at: 2026-08-14T13:36:58+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 1.0
- calibrated_materiality_score: 1.0
- confidence: high
- sec_items: 1.01, 3.02, 3.03, 5.01, 5.02, 5.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1516551/000162828026056966/0001628280-26-056966-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1516551/000162828026056966/skye-20260812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-056966
- JSON: https://secwatch.observer/filing/0001628280-26-056966.json
- Plain text: https://secwatch.observer/filing/0001628280-26-056966.txt

## Key facts
- Executive change
  Tu Diep departed as other_named_officer at Skye Bioscience, Inc..
  - Action: separate
  source text: Tu Diep has entered into a previously disclosed executive employment agreement (the “ Diep Employment Agreement ”) with the Company. In connection with the Transaction, on the date hereof, the Company entered into a separation agreement with Mr. Diep (the “ Diep Separation Agreement ”) pursuant to which Mr. Diep's last day of employment with the Company will be January 31, 2027
  evidence_url: https://www.sec.gov/Archives/edgar/data/1516551/000162828026056966/0001628280-26-056966-index.htm
- Executive change
  Punit Dhillon departed as other_named_officer at Skye Bioscience, Inc..
  - Action: separate
  source text: Punit Dhillon has entered into a previously disclosed executive employment agreement (the “ Dhillon Employment Agreement ”) with the Company. In connection with the Transaction, on the date hereof, the Company entered into a separation agreement with Mr. Dhillon (the “ Dhillon Separation Agreement ”) pursuant to which Mr. Dhillon's last day of employment with the Company will be August 31, 2027
  evidence_url: https://www.sec.gov/Archives/edgar/data/1516551/000162828026056966/0001628280-26-056966-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.